Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 432 | 51 | 380 |
| Samples | 137 | 19 | 117 |
| Peptides | 128 | 16 | 115 |
Function
PGAP3 · Post-GPI attachment to proteins phospholipase 3
This gene encodes a glycosylphosphatidylinositol (GPI)-specific phospholipase that primarily localizes to the Golgi apparatus. This ubiquitously expressed gene is predicted to encode a seven-transmembrane protein that removes unsaturated fatty acids from the sn-2 position of GPI. The remodeling of the constituent fatty acids on GPI is thought to be important for the proper association between GPI-anchored proteins and lipid rafts. The tethering of proteins to plasma membranes via posttranslational GPI-anchoring is thought to play a role in protein sorting and trafficking. Mutations in this gene cause an autosomal recessive form of neurologic hyperphosphatasia with cognitive disability (HPMRS4). Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2017].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000300658 | Q96FM1 | 139 | 101 |
| ENST00000429199 | Q96FM1-3 | 120 | 88 |
| ENST00000378011 | Q96FM1-2 | 106 | 79 |
| ENST00000579146 | J3QKU0* | 63 | 45 |
| ENST00000619169 | A0A087WTP0* | 4 | 4 |
Gene Properties
Recurrent Mutations
All 101 amino-acid changes on canonical ENST00000300658 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PGAP3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PGAP3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 0/210 0% | 25/1899 1% |
| Endometrial Carcinoma | 0/42 0% | 6/612 1% |
| Colorectal Carcinoma | 1/143 1% | 27/3239 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 3/1390 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Head and Neck Carcinoma | 2/85 2% | 3/1574 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Other Solid Cancers | 0/94 0% | 4/1515 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Breast Carcinoma | 2/144 1% | 6/3264 0% |
| Kidney Carcinoma | 1/85 1% | 3/1862 0% |
| Gastric Carcinoma | 0/74 0% | 4/1809 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 1/2550 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
| Hepatocellular Carcinoma | 0/46 0% | 1/2210 0% |
Mutation Distribution
Where PGAP3 is mutated · all tissues, split by cell line vs tissue
How many mutations in PGAP3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 432 mutations in PGAP3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|